BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today the appointment of Burt Adelman, M.D. as Chief Medical Officer. Dr. Adelman will lead the development and regulatory strategy for the Company’s non-histamine-mediated angioedema franchise.
